Inhibitory effect of ginsenoside Rg3 combined with cyclophosphamide on growth and angiogenesis of ovarian cancer.

Primary tabs

field_vote: 
Average: 8 (1 vote)
Publication type: 
Therapeutic intervention: 
Therapeutic Substance(s): 
Disease(s): 
References: 

Chin Med J (Engl). 2007 Apr 5;120(7):584-8.
Inhibitory effect of ginsenoside Rg3 combined with cyclophosphamide on growth and angiogenesis of ovarian cancer.
Xu TM, Xin Y, Cui MH, Jiang X, Gu LP.
Department of Obstetrics and Gynaecology, Second Hospital of Jilin University, Changchun 130041, China.
BACKGROUND:
Ginsenoside Rg3, the main component isolated from ginseng, inhibits
some kinds of tumour growth and angiogenesis. The combination of low
dose chemotherapy and antiangiogenesis inhibitors suppresses growth of
experimental tumours more effectively than conventional therapy. The
effect of this combination on ovarian cancer remains to be evaluated.
Therefore, we investigated the synergism of ginsenoside Rg3 and
cyclophosphamide (CTX) on growth and angiogenesis of human ovarian
cancer.
METHODS: Twenty-eight female athymic mice were divided randomly
into 4 groups of 7: ginsenoside Rg3, CTX, ginsenoside Rg3 and CTX
combination and control, after being transplanted with ovarian cancer
cells (SKOV-3). The mice were given intraperitoneal injection of
ginsenoside Rg3 and CTX for the 10 days following inoculation of SKOV-3
cells. The life quality and number of living days of mice were
recorded. The size of tumour, tumour inhibitive rate, life elongation
rate, proliferating cell nuclear antigen labelling index (PCNALI),
expression of vascular endothelial cell growth factor (VEGF) and
microvessel density (MVD) of the tumour tissues were estimated.

RESULTS: Life quality of mice in ginsenoside Rg3 and combined treatment
groups were better and number of living days longer than control.
Average tumour weights of each treated group were less than control and
there was no significant difference among the treated groups. PCNALI of
treated groups was lower than control. The MVD value and VEGF
expression in treated groups were significantly lower than control and
the MVD values of ginsenoside Rg3 and combined treatment groups were
lower than that of CTX group.
CONCLUSIONS: Ginsenoside Rg3
significantly inhibited growth and angiogenesis of ovarian cancer when
used alone or combined with CTX. Ginsenoside Rg3 and CTX combination
reinforced the antitumour effect each other and improved the living
quality and survival time of mice with tumour.